Immuron CEO, Steven Lydeamore to present at AusBioInvest
26 oct. 2022 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two...
Immuron CEO, Steven Lydeamore, to host an investor webinar
29 août 2022 07h00 HE
|
Immuron Limited
MELBOURNE, Australia, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for...
Immuron to Participate in H.C. Wainwright & Co. BioConnect 2021 Virtual Conference
11 janv. 2021 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral...
Immuron to Commence Non-Deal Investor Roadshow
16 août 2019 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron Prices Underwritten Public Offering of ADSs
17 juil. 2019 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, July 17, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron to Host Investor Webinar on July 18 to Provide Update on Recent Developments
17 juil. 2019 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, July 17, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, announced today that it will participate in an investor...
Immuron to Commence US Non-Deal Institutional Investor Roadshow
19 juin 2019 08h00 HE
|
Immuron Limited
MELBOURNE, Australia, June 19, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron CEO Dr. Gary S. Jacob to Present at the ThinkEquity Conference on May 2, 2019
30 avr. 2019 14h36 HE
|
Immuron Limited
MELBOURNE, Australia, April 30, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron CEO to Present at RedChip Global Online Growth Conference
23 avr. 2018 18h57 HE
|
Immuron Limited
MELBOURNE, Australia, April 23, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), Australian microbiome biopharmaceutical company focused on developing and commercialising orally...